Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Cyclophosphamide Plus Transplantation of Partially HLA-mismatched, CD8+ T Cell-depleted Peripheral Blood Cells for Patients With Myelodysplastic Syndrome , Refractory Acute Myeloid Leukemia, Refractory Lymphoma or Myeloproliferative Disorders

This study has been terminated.
(Poor accrual)
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Sidney Kimmel Comprehensive Cancer Center Identifier:
First received: July 26, 2006
Last updated: August 3, 2016
Last verified: August 2016
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: December 2017
  Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)